This study aims to learn more about chronic lymphocytic leukemia (CLL) by collecting tissue samples and medical information from people with the condition. Researchers hope to understand the causes and biology of CLL better, which could lead to more effective treatments in the future. You may be able to join if you are an adult (18 years or older) with monoclonal B-cell lymphocytosis, any low-grade lymphoproliferative disorder, or chronic lymphocytic leukemia, whether you are a new or existing patient at Dana Farber Cancer Institute or elsewhere. The study will look for new genetic markers that predict how CLL might progress over 20 years. The current status of this study is unclear.

Study design

This is an observational study, meaning researchers will collect information without giving any specific interventions. It plans to enroll up to 2750 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, looking for genomic prognostic markers, will be measured at 20 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.